EVQLV leverages advances in computation to revolutionize the design and development of therapeutic antibodies. We work with partners at the discovery stage to accelerate the speed of antibody discovery. For those collaborators who have preclinical, clinical, or commercial assets, we support the optimization of antibody candidates, develop assets that expand IP protection, and design next generation and innovative immunotherapies. All of our work is performed at accelerated speeds and scale only feasible by leveraging computational tools that learn from massive and diverse datasets.